drugset / Trial / NCT06190912
Safety of Bryostatin in Patients With MS
NaSingle-groupOpen-labelTreatment
Summary
This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).
Timeline
- Start
- 2024-06-26
- Primary completion
- 2025-03-15
- Completion
- 2025-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bryostatin 1 | Small molecule | 20 ug | Intravenous |